Completed PHASE3 INTERVENTIONAL 1-arm NCT05372653

A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis

A Phase 3, Multicenter, Open-label, Uncontrolled Trial to Evaluate the Efficacy and Safety of OPA-15406 Ointment in Infants Younger Than 2 Years of Age With Atopic Dermatitis

Sponsor: Otsuka Pharmaceutical Co., Ltd.

Conditions Atopic Dermatitis (AD)

Interventions OPA-15406

Updated 7 times since 2022 Last updated: Mar 12, 2025 Started: May 23, 2022 Primary completion: Dec 29, 2022 Completion: Nov 29, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atopic Dermatitis (AD), this trial is completed. The trial is conducted by Otsuka Pharmaceutical Co., Ltd. and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Apr 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2024 — Jul 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2023 — Mar 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE3
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE3

First recorded

May 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Pharmaceutical Co., Ltd.

Data source: Otsuka Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Isumi, Japan